Search bioRxiv⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2020.02.17.952085

Comprehensive Network Analysis and Experimental Verification of Dedu Safflower's Influence on Ascites Hepatocarcinoma

Bao, L.·Wang, L.·Li, S.
View original source ↗Export metadata ↓

Abstract

BackgroundDedu Safflower Powder is a kind of classical prescription of Mongolian Medicine, and its main ingredients are the safflower and the Scabiosa tschiliensis. In the former Mongolian Medicine clinical practice, Dedu Safflower Powder, etc. had obvious effect on curing hepatocarcinoma so as to ease ascites. But the principle of Dedu Safflower Powders curing ascites hepatocarcinoma has been not clear. AimH22 mouse hepatocarcinoma ascites models are used for researching the safflower and the Scabiosa tschiliensiss function of jointly being against hepatocarcinoma ascites, and for verifying their possible combination principle (miR-23a-DAPK1-PVT1 signal axis). MethodThrough simulating an interaction network of the safflower and the Scabiosa tschiliensis with target spots, the function target was predicted. H22 mouse hepatocarcinoma ascites models were randomly divided into a blank contrast group, a model contrast group, a safflower group, a Scabiosa tschiliensis group and a compatibility group of the safflower/the Scabiosa tschiliensis. On the 10th day, mice were killed to measure their weights and abdominal perimeters, also to collect ascites and blood for physical examinations. Kidney tissues were dissected at once and fixed in paraformaldehyde, for a real-time quantitative polymerase chain reaction (qRT-PCR) analysis. ResultIn the network, the DAPK1-PVT1 interaction showed the biggest edge betweenness, so it was predicted that DAPK1 and PVT1 were respectively presumed targets of the safflower and the Scabiosa tschiliensis. Compared with the model contrast group, the safflower group, the Scabiosa tschiliensis group and the safflower/Scabiosa tschiliensis group all had decreasing ascites volumes, body weights, abdominal perimeters. Compared with the model group, the safflower group and the safflower/Scabiosa tschiliensis group had rising DAPK1 expressions (p<0.05), while the safflower group had more obvious increasing DAPK1 (p<0.01); the Scabiosa tschiliensis group and the safflower/Scabiosa tschiliensis group had lowering PVT1 expressions (p<0.05), while the Scabiosa tschiliensis group had more obvious lowering PVT1 (p<0.01); the safflower group, the Scabiosa tschiliensis group and the safflower/Scabiosa tschiliensis group had lowering miR-23a expressions (p<0.05), while the safflower/Scabiosa tschiliensis group had more obvious lowering (p<0.01). ConclusionDAPK1 and PVT1 are respectively the presumed targets of the safflower and the Scabiosa tschiliensis. So Dedu Safflower Powder has good effects on ascites hepatocarcinoma, and that function may be partly related to regulation of miR-23a-DAPK1-PVT1 signal axis.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Bao, L., Wang, L., Li, S.. 2020-02-18. Comprehensive Network Analysis and Experimental Verification of Dedu Safflower's Influence on Ascites Hepatocarcinoma. https://doi.org/10.1101/2020.02.17.952085

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Ex vivo human tumor slices more accurately predict patient responses to an oncolytic virus than in vivo mouse models

Immunotherapies, including oncolytic viruses (OV), are promising therapies that can enhance anti-tumor immune responses. However, preclinical success of immunotherapies in mouse models has not always translated to clinical benefit in cancer patients. This study compared preclinical efficacy and mechanism of action for ASP9801, a vaccinia virus expressing IL-7 and IL-12, using mouse models of colorectal cancer (CRC) in vivo and in human organotypic tumor slice models ex vivo. The murine surrogate for ASP9801 significantly reduced tumor volumes in treated and abscopal tumors in two different CRC models in vivo (MC38 and RO100). Treatment efficacy was accentuated when combined with anti-PD1 treatment, and single-cell RNA sequencing analysis revealed depletion of tumor cells and increased T cell infiltration and activation in both treated and abscopal tumors. However, human tissue analysis ex vivo (E-slices) using PDX models and patient samples showed that ASP9801 is not effective in CRC, consistent with clinical trial results. On the other hand, ASP9801 was highly effective in GBM, indicating indication-specific efficacy of ASP9801, and how E-slice assays can be used to identify treatment-sensitive indications. This study demonstrates the superiority of E-slices over mouse models for predicting clinical response and its utility in planning clinical trials.

cancer biology↗
bioRxiv2026

Immune-cell depleted diffuse large B-cell lymphomas have reduced expression of MHC class I

Immunotherapy has transformed treatment for many cancers. In the aggressive and genetically heterogeneous diffuse large B-cell lymphoma (DLBCL), CD19 CAR T-cell therapy is highly effective, whereas immune checkpoint blockade has shown limited benefit. Loss of MHC expression is a common mechanism to escape T-cell cytotoxicity, and loss of MHC class I (MHC-I) and II are frequent in DLBCL. We applied imaging mass cytometry to diagnostic biopsies from younger, high-risk DLBCL patients to map the tumor microenvironment (TME) spatial architecture in relation to tumor cell MHC expression, mutational status, transcriptomic and proteomic profiles. Neighborhood analyses identified four TME subtypes: immune-cell depleted and three immune-infiltrated types (mixed, CD4 T cell-rich, CD8 T-cell/macrophage-rich). Depleted cases had shorter overall survival (p = 0.033) and increased expression of proteins involved in DNA replication and proliferation markers compared to infiltrated cases. Tumor cell MHC-I expression was heterogeneous. Cases with low frequency of MHC-I-pos tumor cells were enriched for the depleted TME type. MHC-I-pos tumor cells were surrounded by CD4 and CD8 T cells and M1 macrophages, whereas MHC-I-neg tumor cells were closer to other MHC-I-neg tumor cells. These findings suggest that TME-based classification incorporating tumor cell MHC-I status may improve individualized immunotherapy selection.

cancer biology↗
bioRxiv2026

Cross-species analysis links cell-cell communication rewiring to NOTCH2 during serous endometrial carcinogenesis

Cell-cell interactions shape the fate of mutant cells during cancer initiation but how these interactions evolve during progression to pathologically recognizable lesions remain poorly understood. Here, we investigated cell-cell communication during serous endometrial carcinoma (SEC; also known as uterine serous carcinoma) development using a lineage-traceable mouse model and cross-species analyses of the mouse and human neoplastic endometrium. In mice, the early, pre-dysplastic stage was marked by a global decrease in inferred cell-cell interactions, followed by extensive communication network rewiring during neoplastic progression. Pathway-specific analysis revealed a similar pattern for NOTCH signaling, with NOTCH2 emerging as the dominant NOTCH receptor in Trp53/Rb1-mutant immature epithelial cells. Functionally, NOTCH2 promoted the outgrowth of more proliferative mutant organoids. Cross-species transcriptomic analysis identified conserved immature epithelial states in mouse and human neoplastic endometrial epithelium. In human tissues, NOTCH2 was overexpressed in serous endometrial intraepithelial carcinoma, a precursor of SEC, and in overt SEC. Furthermore, elevated NOTCH2 expression was associated with poor patient survival. These findings link cell-cell communication rewiring during experimental SEC development to conserved neoplastic epithelial states and identify NOTCH2 as an early marker and a potential target of disease interception.

cancer biology↗